PMID- 36378042
OWN - NLM
STAT- MEDLINE
DCOM- 20221118
LR  - 20230415
IS  - 2589-451X (Electronic)
IS  - 0255-2922 (Print)
IS  - 0255-2922 (Linking)
VI  - 42
IP  - 6
DP  - 2022 Dec
TI  - Efficacy and safety of acupoint application for allergic rhinitis: a systematic 
      review and Meta-analysis of randomized controlled trials.
PG  - 858-868
LID - 10.19852/j.cnki.jtcm.2022.06.003 [doi]
AB  - OBJECTIVE: To use evidence-based medicine to explore the efficacy of acupoint 
      application (AA) for allergic rhinitis (AR) at different time points and its 
      safety. METHODS: We searched 7 databases (PubMed, Cochrane, Embase, China 
      National Knowledge Infrastructure, Wanfang Database, China Science and Technology 
      Journal Database, and China Biology Medicine disc) as well as the international 
      clinical trial registration platform from January 2010 to March 2020 for 
      randomized controlled trials (RCTs) comparing the efficacy of AA versus placebo, 
      Western Medicine or other alternative therapies on AR. Risk of bias was assessed 
      according to the Cochrane handbook, and statistical analysis was performed using 
      RevMan 5.3. Outcomes included the total effective rate, recurrence rate, total 
      nasal symptom score (TNSS), visual analogue scale (VAS), quality of life measured 
      by the Rhinitis Quality of Life Questionnaire (RQLQ) or Short Form-36 (SF-36), 
      adverse events, and biomarkers including immunoglobulin E (IgE), peripheral blood 
      eosinophil count (EOS), interleukin-4 (IL-4), and interferon gamma (INF-gamma). 
      RESULTS: Twenty-eight RCTs involving 3282 participants were included. The 
      short-term and long-term efficacy of AA was significantly better than placebo, 
      including better total effective rate [: 3.05, 95% (1.84, 5.07), after treatment; 
      : 9.29, 95% (2.57, 33.66), at 6 months], lower recurrence rate [: 0.55, 95% 
      (0.45, 0.66), at 6 months; : 0.65, 95% (0.57, 0.74), at 1 year], lower TNSS [: 
      -3.09, 95% (-3.58, -2.61), after treatment], and lower RQLQ [: -14.79, 95% 
      (-21.49, -8.10), after treatment; : -11.92, 95% (-17.40, -6.45), at 4-6 months]. 
      Compared with Western Medicine, AA had better long-term total effective rate [: 
      1.33, 95%CI (1.05, 1.69), at 3 months; : 1.49, 95% 1.22 to 1.81, at 1 year) and 
      lower recurrence rate [: 0.48, 95% (0.39, 0.58), at 6 months; : 0.45, 95% (0.33, 
      0.60), at 1 year]. AA had better long-term total effective rate versus 
      acupuncture [: 2.06, 95% (1.28, 3.31), at 1 year] or oral Chinese medicine [: 
      1.21, 95% (1.09, 1.34), >/= 6 months]. Both AA and Western Medicine can reduce 
      serum levels of IgE, EOS, and IL-4 after treatment. The main adverse event of AA 
      was local skin reaction without systemic side effects. CONCLUSIONS: The 
      short-term (within one month) and long-term (at 3 months, 6 months and 1 year) 
      efficacy of acupoint application on AR was better than that of placebo. The 
      long-term efficacy of acupoint application was superior to that of Western 
      Medicine (at 3 months, 6 months and 1 year), oral Chinese medicine (at more than 
      6 months) and acupuncture (at 1 year). AA can reduce serum IgE, EOS, and IL-4 
      level of AR patients in a short run. Acupoint application is safe, but severe 
      skin reactions can reduce patient compliance.
FAU - Mengxia, Shen
AU  - Mengxia S
AD  - The First School of Clinical Medicine of Zhejiang Chinese Medical University, 
      Hangzhou 310053, China.
FAU - Wenfang, Shang
AU  - Wenfang S
AD  - The First School of Clinical Medicine of Zhejiang Chinese Medical University, 
      Hangzhou 310053, China.
FAU - Jiangxia, W U
AU  - Jiangxia WU
AD  - The First School of Clinical Medicine of Zhejiang Chinese Medical University, 
      Hangzhou 310053, China.
FAU - Zelin, Y U
AU  - Zelin YU
AD  - The First School of Clinical Medicine of Zhejiang Chinese Medical University, 
      Hangzhou 310053, China.
FAU - Lihua, Xuan
AU  - Lihua X
AD  - Department of acupuncture and moxibustion, the First Affiliated Hospital of 
      Zhejiang Chinese Medical University, Hangzhou 310006, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
PL  - China
TA  - J Tradit Chin Med
JT  - Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan
JID - 8211546
RN  - 207137-56-2 (Interleukin-4)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Humans
MH  - *Acupuncture Points
MH  - Interleukin-4
MH  - Randomized Controlled Trials as Topic
MH  - *Rhinitis, Allergic/therapy
MH  - Immunoglobulin E
PMC - PMC9924800
OTO - NOTNLM
OT  - Meta-analysis
OT  - acupoint application
OT  - randomized controlled trial
OT  - rhinitis, allergic
OT  - systematic review
EDAT- 2022/11/16 06:00
MHDA- 2022/11/19 06:00
PMCR- 2022/12/15
CRDT- 2022/11/15 09:53
PHST- 2022/11/15 09:53 [entrez]
PHST- 2022/11/16 06:00 [pubmed]
PHST- 2022/11/19 06:00 [medline]
PHST- 2022/12/15 00:00 [pmc-release]
AID - 1667533141555-710788075 [pii]
AID - 0255-2922-42-6-858 [pii]
AID - 10.19852/j.cnki.jtcm.2022.06.003 [doi]
PST - ppublish
SO  - J Tradit Chin Med. 2022 Dec;42(6):858-868. doi: 10.19852/j.cnki.jtcm.2022.06.003.